Drugs / Ad5FGF-4
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/32 trials · 1 missed | ||||||
| Phase 2/3 | NCT00185263 | Mar 2002 → Jan 2005 | — | Cardium Therapeutics | Unknown | No outcome recorded |
| Phase 2/3 | NCT00346437 | Oct 2001 → Jan 2005 | — | Cardium Therapeutics | Completed | Missed primary |
| Phase 32 trials · 1 missed | ||||||
| Phase 3 | NCT02928094 | Jan 2023 → Mar 2024 | intermediate coronary syndrome | Angionetics Inc. | Unknown | No outcome recorded |
| Phase 3 | NCT00438867 | May 2007 → Nov 2009 | intermediate coronary syndrome | Cardium Therapeutics | Unknown | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad5FGF-4 | “Ad5FGF-4 (alferminogene tadenovec, Generx, Berlex Biosciences, Richmond, California)” PMID 17825712 ↗ Aug 2007 |
| Known as | alferminogene tadenovec | “Ad5FGF-4 (alferminogene tadenovec, Generx, Berlex Biosciences, Richmond, California)” PMID 17825712 ↗ Aug 2007 |
| Known as | Generx | “Ad5FGF-4 (alferminogene tadenovec, Generx, Berlex Biosciences, Richmond, California)” PMID 17825712 ↗ Aug 2007 |
| Route | Other | “single intracoronary infusion of Ad5FGF-4” NCT00185263 ↗ |
| Target | FGF4 | “Adenovirus serotype-5 mediated human fibroblast growth factor-4 gene transfer” NCT00438867 ↗ |